Kunalkumar Vyas, DO
Ophthalmology · Dayton, OHNPI 1235494394
Payments from drug & device makers
What this record shows
Johnson & Johnson Surgical Vision, Inc. accounts for 61.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $1,506 and has fallen 88.4% since, to $175 in 2025.
Across 36 payments — averaging $63.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1K
- Bausch & Lomb Americas Inc.$164
- NEW World Medical,inc.$138
- Rxsight Inc$130
- AbbVie$91
- Alcon$69
- plus $296 from 9 others
Across 9 payments — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$18K
What the payments were for
- Travel & lodging$1,15250%
- Food & beverage$1,13950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 6 | $1,403 |
| Bausch & Lomb Americas Inc. | 4 | $164 |
| NEW World Medical,inc. | 4 | $138 |
| Rxsight Inc | 4 | $130 |
| AbbVie | 2 | $91 |
| Alcon | 3 | $69 |
| Astellas Pharma US Inc | 2 | $58 |
| Sight Sciences, Inc. | 3 | $52 |
| Glaukos Corporation | 2 | $43 |
| Coherus Oncology, Inc. | 1 | $37 |
| Oyster Point Pharma, Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
| Ivantis, Inc | 1 | $17 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,291 in reported general payments places this provider in the 65th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 64 | $4,612 |
| Prednisolone Acetate | 11 | $499 |
| Ketorolac Tromethamine | 17 | $375 |
| Ciprofloxacin Hcl | 14 | $156 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Dayton
- Amy MillerDayton$526K
- Patrick SpencerDayton$13K
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Sunil SrivastavaCleveland$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.